{"id":1714,"date":"2000-07-01T12:03:00","date_gmt":"2000-07-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/vergleich-von-losartan-mit-captopril-bei-herzinsuffizienz-die-elite-ii-studie"},"modified":"2000-07-01T12:03:00","modified_gmt":"2000-07-01T10:03:00","slug":"vergleich-von-losartan-mit-captopril-bei-herzinsuffizienz-die-elite-ii-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/vergleich-von-losartan-mit-captopril-bei-herzinsuffizienz-die-elite-ii-studie","title":{"rendered":"Vergleich von Losartan mit Captopril bei Herzinsuffizienz. Die ELITE-II-Studie"},"content":{"rendered":"<p>Unter der Leitung von B. Pitt wurden 1997 die Ergebnisse der ELITE-Studie publiziert (1, s.a. 2), in der die Effekte von Captopril (ACE-Hemmer) und Losartan (Angiotensin-II-Typ-A1-Rezeptor-Blocker) auf die Nierenfunktion bei \u00e4lteren Patienten mit Herzinsuffizienz verglichen werden sollten (prim\u00e4rer Endpunkt). Als \u00fcberraschender Nebenbefund dieser \u00fcber 48 Wochen laufenden Studie ergab sich, da\u00df Losartan verglichen mit Captopril [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unter der Leitung von B. Pitt wurden 1997 die Ergebnisse der ELITE-Studie publiziert (1, s.a. 2), in der die Effekte von Captopril (ACE-Hemmer) und Losartan (Angiotensin-II-Typ-A1-Rezeptor-Blocker) auf die Nierenfunktion bei \u00e4lteren Patienten mit Herzinsuffizienz verglichen werden sollten (prim\u00e4rer Endpunkt). Als \u00fcberraschender Nebenbefund dieser \u00fcber 48 Wochen laufenden Studie ergab sich, da\u00df Losartan verglichen mit Captopril [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,316,309,312,314,313,315,317,320,311,307,319,310,308,3864,321,306],"class_list":["post-1714","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-captopril","tag-elite-ii-studie","tag-losartan","tag-sartane"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1714"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1714\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}